Abstract 3706: Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan

Research output: Contribution to journalArticle

Abstract

Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAChronic kidney disease (CKD) was the tenth leading cause of death in Taiwan. as the fifth stage of progressive CKD. Various therapeutic modalities including hemodialysis (HD),peritoneal dialysis (PD) and renal transplantation (RT) modify the risks of systemic chronic diseases in end-stage renal disease (ESRD) patients remains unclear.A total of 18,081 newly diagnosed ESRD patients and 54,243 controls matched for age, gender and index date were recruited from the National Health Insurance Research Database in Taiwan. The ESRD status was confirmed by the registry of catastrophic illness. The incidence of cancer was identified through cross-referencing with the National Cancer Registry Database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox proportional hazards model. Kaplan-Meier method were used for all analyses. Significant higher incidence rate ratios (IRRs) of bladder cancer of 7.0, 9.5 and 14.4 were found for ESRD patients undergoing HD, PD and RT, respectively. The IRRs of kidney cancer also represent a similar risk pattern. We observed that significant bladder cancer risks were observed among ESRD patients undergoing HD (HR = 10.0), PD (HR = 12.8) and RT (17.7) after the adjustment for age, gender and co-morbidities. In addition, significant kidney cancer risks of 11.2, 17.1 and 33.7 were also found for ESRD patients undergoing HD, PD and RT, respectively. In conclusion, different therapeutic modalities could modify the risks of bladder and kidney cancers in ESRD patients in Taiwan.Citation Format: Wei-Tang Kao, Cheng-Huang Shen, Kee-Thai Kiu, Hsin-An Chen, Chia-Chang Wu, Yuan-Hung Wang. Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3706. doi:10.1158/1538-7445.AM2015-3706
Original languageTraditional Chinese
JournalCancer Research
Volume75
Issue number15 Supplement
DOIs
Publication statusPublished - Aug 1 2015

Cite this

@article{a7c911c505ca4f4086024a825490197f,
title = "Abstract 3706: Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan",
abstract = "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAChronic kidney disease (CKD) was the tenth leading cause of death in Taiwan. as the fifth stage of progressive CKD. Various therapeutic modalities including hemodialysis (HD),peritoneal dialysis (PD) and renal transplantation (RT) modify the risks of systemic chronic diseases in end-stage renal disease (ESRD) patients remains unclear.A total of 18,081 newly diagnosed ESRD patients and 54,243 controls matched for age, gender and index date were recruited from the National Health Insurance Research Database in Taiwan. The ESRD status was confirmed by the registry of catastrophic illness. The incidence of cancer was identified through cross-referencing with the National Cancer Registry Database. Hazard ratios (HRs) and 95{\%} confidence intervals (CIs) were estimated by a Cox proportional hazards model. Kaplan-Meier method were used for all analyses. Significant higher incidence rate ratios (IRRs) of bladder cancer of 7.0, 9.5 and 14.4 were found for ESRD patients undergoing HD, PD and RT, respectively. The IRRs of kidney cancer also represent a similar risk pattern. We observed that significant bladder cancer risks were observed among ESRD patients undergoing HD (HR = 10.0), PD (HR = 12.8) and RT (17.7) after the adjustment for age, gender and co-morbidities. In addition, significant kidney cancer risks of 11.2, 17.1 and 33.7 were also found for ESRD patients undergoing HD, PD and RT, respectively. In conclusion, different therapeutic modalities could modify the risks of bladder and kidney cancers in ESRD patients in Taiwan.Citation Format: Wei-Tang Kao, Cheng-Huang Shen, Kee-Thai Kiu, Hsin-An Chen, Chia-Chang Wu, Yuan-Hung Wang. Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3706. doi:10.1158/1538-7445.AM2015-3706",
author = "Wei-Tang Kao and Cheng-Huang Shen and Kee-Thai Kiu and Hsin-An Chen and Chia-Chang Wu and Yuan-Hung Wang",
year = "2015",
month = "8",
day = "1",
doi = "10.1158/1538-7445.AM2015-3706",
language = "繁體中文",
volume = "75",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15 Supplement",

}

TY - JOUR

T1 - Abstract 3706: Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan

AU - Kao, Wei-Tang

AU - Shen, Cheng-Huang

AU - Kiu, Kee-Thai

AU - Chen, Hsin-An

AU - Wu, Chia-Chang

AU - Wang, Yuan-Hung

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAChronic kidney disease (CKD) was the tenth leading cause of death in Taiwan. as the fifth stage of progressive CKD. Various therapeutic modalities including hemodialysis (HD),peritoneal dialysis (PD) and renal transplantation (RT) modify the risks of systemic chronic diseases in end-stage renal disease (ESRD) patients remains unclear.A total of 18,081 newly diagnosed ESRD patients and 54,243 controls matched for age, gender and index date were recruited from the National Health Insurance Research Database in Taiwan. The ESRD status was confirmed by the registry of catastrophic illness. The incidence of cancer was identified through cross-referencing with the National Cancer Registry Database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox proportional hazards model. Kaplan-Meier method were used for all analyses. Significant higher incidence rate ratios (IRRs) of bladder cancer of 7.0, 9.5 and 14.4 were found for ESRD patients undergoing HD, PD and RT, respectively. The IRRs of kidney cancer also represent a similar risk pattern. We observed that significant bladder cancer risks were observed among ESRD patients undergoing HD (HR = 10.0), PD (HR = 12.8) and RT (17.7) after the adjustment for age, gender and co-morbidities. In addition, significant kidney cancer risks of 11.2, 17.1 and 33.7 were also found for ESRD patients undergoing HD, PD and RT, respectively. In conclusion, different therapeutic modalities could modify the risks of bladder and kidney cancers in ESRD patients in Taiwan.Citation Format: Wei-Tang Kao, Cheng-Huang Shen, Kee-Thai Kiu, Hsin-An Chen, Chia-Chang Wu, Yuan-Hung Wang. Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3706. doi:10.1158/1538-7445.AM2015-3706

AB - Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PAChronic kidney disease (CKD) was the tenth leading cause of death in Taiwan. as the fifth stage of progressive CKD. Various therapeutic modalities including hemodialysis (HD),peritoneal dialysis (PD) and renal transplantation (RT) modify the risks of systemic chronic diseases in end-stage renal disease (ESRD) patients remains unclear.A total of 18,081 newly diagnosed ESRD patients and 54,243 controls matched for age, gender and index date were recruited from the National Health Insurance Research Database in Taiwan. The ESRD status was confirmed by the registry of catastrophic illness. The incidence of cancer was identified through cross-referencing with the National Cancer Registry Database. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox proportional hazards model. Kaplan-Meier method were used for all analyses. Significant higher incidence rate ratios (IRRs) of bladder cancer of 7.0, 9.5 and 14.4 were found for ESRD patients undergoing HD, PD and RT, respectively. The IRRs of kidney cancer also represent a similar risk pattern. We observed that significant bladder cancer risks were observed among ESRD patients undergoing HD (HR = 10.0), PD (HR = 12.8) and RT (17.7) after the adjustment for age, gender and co-morbidities. In addition, significant kidney cancer risks of 11.2, 17.1 and 33.7 were also found for ESRD patients undergoing HD, PD and RT, respectively. In conclusion, different therapeutic modalities could modify the risks of bladder and kidney cancers in ESRD patients in Taiwan.Citation Format: Wei-Tang Kao, Cheng-Huang Shen, Kee-Thai Kiu, Hsin-An Chen, Chia-Chang Wu, Yuan-Hung Wang. Risk of bladder and kidney cancers in end-stage renal disease patients: a nationwide, population-based study in Taiwan. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3706. doi:10.1158/1538-7445.AM2015-3706

U2 - 10.1158/1538-7445.AM2015-3706

DO - 10.1158/1538-7445.AM2015-3706

M3 - 文章

VL - 75

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15 Supplement

ER -